Delving into the Latest Updates on LY-3006072 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Eli Lilly & Co.

Active Organization-

Inactive Organization

Eli Lilly & Co.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. The study drug will be given in the morning or evening with or without a meal.
This is the first time that this study drug is being given to humans. This study is for research purposes only and is not intended to treat any medical condition.

Start Date24 Jul 2012

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-3006072

Login to view more data

100 Translational Medicine associated with LY-3006072

Login to view more data

100 Patents (Medical) associated with LY-3006072

Login to view more data

100 Deals associated with LY-3006072

Login to view more data